Clinical Trial Update: Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of reverse transcriptase inhibitors for Aicardi Goutières Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aicardi-goutières Syndrome

Drugs mentioned

• Reverse Transcriptase Inhibitors

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Aicardi Goutières Syndrome | Phase 1, Phase 2 | Status: WITHDRAWN